Page last updated: 2024-10-31

modafinil and Depression, Involutional

modafinil has been researched along with Depression, Involutional in 46 studies

Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.

Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.

Research Excerpts

ExcerptRelevanceReference
"Twelve weeks of modafinil augmentation relieved excessive sleepiness, reduced fatigue, and improved patients' overall clinical condition, including mood."9.12Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. ( Arora, S; DeBattista, C; Fava, M; Hughes, RJ; Thase, ME, 2006)
"Previous studies suggest that adjunctive modafinil treatment provides benefit for patients with depression with significant sleepiness and fatigue."9.12Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. ( Crits-Christoph, P; Dunlop, BW; Evans, DL; Gallop, RJ; Garlow, SJ; Hirschowitz, J; Ninan, PT; Rickels, K; Solvason, HB, 2007)
"Modafinil combined with an SSRI at treatment initiation may enhance the onset and degree of symptom benefit in patients with MDD and fatigue."9.11Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. ( Glass, SJ; Hassman, HA; McManus, FC; Ninan, PT, 2004)
"These findings suggest that modafinil is a well-tolerated and potentially effective augmenting agent for SSRI partial responders with fatigue and sleepiness."9.11A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. ( DeBattista, C; Fava, M; Thase, ME, 2005)
"Modafinil may be a useful adjunct therapy for the short-term management of residual fatigue and sleepiness in patients who are partial responders to antidepressant therapy."9.10Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. ( DeBattista, C; Doghramji, K; Fieve, RR; Menza, MA; Rosenthal, MH, 2003)
"This is a case report of a patient with narcolepsy treated simultaneously with modafinil and tranylcypromine."7.72Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report. ( Clemons, WE; Makela, E; Young, J, 2004)
"19] after taking 200 mg versus 100 mg and 0 mg of modafinil, while fluency increased linearly with dosage at a trend level [F(1,18) = 4."7.11A multi-pronged investigation of option generation using depression, PET and modafinil. ( Ang, YS; Belleau, EL; Boyden, S; Breiger, M; Brunner, D; Cusin, C; Dillon, DG; El Fakhri, G; Fava, M; Gelda, SE; Hayden, E; Hooker, J; Jahan, A; Kang, MS; Levine, MT; Meyer, AK; Normandin, M; Petibon, Y; Pizzagalli, DA; Schroder, H, 2022)
"Twelve weeks of modafinil augmentation relieved excessive sleepiness, reduced fatigue, and improved patients' overall clinical condition, including mood."5.12Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. ( Arora, S; DeBattista, C; Fava, M; Hughes, RJ; Thase, ME, 2006)
"Previous studies suggest that adjunctive modafinil treatment provides benefit for patients with depression with significant sleepiness and fatigue."5.12Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. ( Crits-Christoph, P; Dunlop, BW; Evans, DL; Gallop, RJ; Garlow, SJ; Hirschowitz, J; Ninan, PT; Rickels, K; Solvason, HB, 2007)
"Modafinil combined with an SSRI at treatment initiation may enhance the onset and degree of symptom benefit in patients with MDD and fatigue."5.11Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. ( Glass, SJ; Hassman, HA; McManus, FC; Ninan, PT, 2004)
"These findings suggest that modafinil is a well-tolerated and potentially effective augmenting agent for SSRI partial responders with fatigue and sleepiness."5.11A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. ( DeBattista, C; Fava, M; Thase, ME, 2005)
"Modafinil may be a useful adjunct therapy for the short-term management of residual fatigue and sleepiness in patients who are partial responders to antidepressant therapy."5.10Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. ( DeBattista, C; Doghramji, K; Fieve, RR; Menza, MA; Rosenthal, MH, 2003)
"The use of traditional psychostimulants (methylphenidate and dexamphetamine) and stimulant-like drugs (modafinil and armodafinil) for the treatment of depression is a growing concern given the lack of research evidence supporting their effectiveness."4.93Stimulants for depression: On the up and up? ( Bassett, D; Boyce, P; Byrow, Y; Hopwood, M; Lyndon, W; Malhi, GS; Mulder, R; Murray, G; Porter, R; Singh, A, 2016)
"Modafinil is an effective augmentation strategy for acute depressive episodes, including for symptoms of fatigue, in both unipolar and bipolar disorders."4.89Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. ( Costafreda, SG; Fu, CH; Goss, AJ; Kaser, M; Sahakian, BJ, 2013)
"This is a case report of a patient with narcolepsy treated simultaneously with modafinil and tranylcypromine."3.72Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report. ( Clemons, WE; Makela, E; Young, J, 2004)
"19] after taking 200 mg versus 100 mg and 0 mg of modafinil, while fluency increased linearly with dosage at a trend level [F(1,18) = 4."3.11A multi-pronged investigation of option generation using depression, PET and modafinil. ( Ang, YS; Belleau, EL; Boyden, S; Breiger, M; Brunner, D; Cusin, C; Dillon, DG; El Fakhri, G; Fava, M; Gelda, SE; Hayden, E; Hooker, J; Jahan, A; Kang, MS; Levine, MT; Meyer, AK; Normandin, M; Petibon, Y; Pizzagalli, DA; Schroder, H, 2022)
" We evaluated the effect of daily dosing with armodafinil on the pharmacokinetics and safety of the CYP3A4 substrate aripiprazole, an atypical antipsychotic used to treat bipolar I disorder."2.80Evaluation of Potential Pharmacokinetic Drug-Drug Interaction between Armodafinil and Aripiprazole in Healthy Adults. ( Bond, M; Darwish, M; Hellriegel, ET; Robertson, P; Yang, R, 2015)
" Adverse events (AEs) observed in > 5% of either the armodafinil 150 mg or placebo groups and more frequently with 150 mg armodafinil were diarrhea (9% [17/198] vs 7% [13/199]), and nausea (6% [11/198] vs 5% [9/199]), respectively."2.79Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial. ( Calabrese, JR; Frye, MA; Ketter, TA; Yang, R, 2014)
"Armodafinil was not associated with an increased incidence and/or severity of suicidality, depression, or mania or with changes in metabolic profile measurements."2.75Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. ( Calabrese, JR; Frye, MA; Ketter, TA; Tiller, JM; Yang, R; Youakim, JM, 2010)
"Modafinil is a wake-promoting agent approved by the Federal Drug Administration for the treatment of narcolepsy."2.71A prospective trial of modafinil as an adjunctive treatment of major depression. ( DeBattista, C; Ghebremichael, R; Lembke, A; Poirier, J; Solvason, HB, 2004)
"Modafinil has proven to be effective in the treatment of residual symptoms of unipolar and bipolar depression such as fatigue, excessive sleepiness and some cognitive impairment."2.66The role of eugeroics in the treatment of affective disorders. ( Cubała, WJ; Urban, AE, 2020)
"Modafinil was associated with improvements in executive functioning after 4 weeks of open-label adjunctive treatment in currently depressed participants."2.61The Potential Procognitive Effects of Modafinil in Major Depressive Disorder: A Systematic Review. ( Bhat, V; Kennedy, SH; McInerney, SJ; Vaccarino, SR, 2019)
" Approaches to the management of residual symptoms include addressing treatment-emergent side effects and co-morbid conditions, optimizing antidepressant dosing and using augmentation therapy."2.43Pharmacological approaches to the treatment of residual symptoms. ( Fava, M, 2006)
"Fatigue and sleepiness (hypersomnia) are symptoms that are highly prevalent in patients with major depressive disorder (MDD)."2.43Symptoms of fatigue and sleepiness in major depressive disorder. ( Baldwin, DS; Papakostas, GI, 2006)
"Standard antidepressants approved for treating major depressive disorder fail to exert efficacy in bipolar depression."1.91High-dose armodafinil in treatment-refractory bipolar depression. ( Kwok, WY; Nasrallah, HA; Stephens, V, 2023)
"Modafinil is a drug with stimulanteffect on the central nervous system by binding to norepinephrineand dopamine transporters and consequently increasing synapticnorepinephrine and dopamine levels."1.51[Use of Modafinil in Co-existing Major Depression and ErectileDysfunction: A Case Report]. ( Karaş, H; Kaşer, M, 2019)
" Subjects assigned to group 1 received a dose of carbamazepine (200 mg) alone and a dose after pretreatment with daily dosing of armodafinil (titrated to 250 mg/d)."1.42Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults. ( Bond, M; Darwish, M; Hellriegel, ET; Robertson, P; Yang, R, 2015)
"Modafinil has a novel mechanism of action and may have antidepressant properties."1.33A retrospective chart review of the effects of modafinil on depression as monotherapy and as adjunctive therapy. ( Price, CS; Taylor, FB, 2005)

Research

Studies (46)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's24 (52.17)29.6817
2010's19 (41.30)24.3611
2020's3 (6.52)2.80

Authors

AuthorsStudies
Ang, YS1
Cusin, C1
Petibon, Y1
Dillon, DG1
Breiger, M1
Belleau, EL1
Normandin, M1
Schroder, H1
Boyden, S1
Hayden, E1
Levine, MT1
Jahan, A1
Meyer, AK1
Kang, MS1
Brunner, D1
Gelda, SE1
Hooker, J1
El Fakhri, G1
Fava, M5
Pizzagalli, DA1
Kwok, WY1
Stephens, V1
Nasrallah, HA1
Karaş, H1
Kaşer, M2
Vaccarino, SR1
McInerney, SJ1
Kennedy, SH2
Bhat, V1
Urban, AE1
Cubała, WJ1
McIntyre, RS1
Lee, Y1
Zhou, AJ1
Rosenblat, JD1
Peters, EM1
Lam, RW1
Rong, C1
Jerrell, JM1
Goss, AJ1
Costafreda, SG1
Sahakian, BJ1
Fu, CH1
Calabrese, JR2
Frye, MA2
Yang, R5
Ketter, TA2
El-Mallakh, RS1
Ostacher, MJ1
Darwish, M2
Bond, M2
Hellriegel, ET2
Robertson, P2
Andrade, C1
Malhi, GS1
Byrow, Y1
Bassett, D1
Boyce, P1
Hopwood, M1
Lyndon, W1
Mulder, R1
Porter, R1
Singh, A1
Murray, G1
Otto, MW1
Lee, J1
Hofmann, SG1
Hearon, BA1
Smits, JA1
Rosenfield, D1
Wright, JH1
Ng, B2
Pae, CU1
Patkar, AA1
Masand, PS1
IsHak, WW1
Davis, M1
Jeffrey, J1
Balayan, K1
Pechnick, RN1
Bagot, K1
Rapaport, MH1
Krystal, AD1
Harsh, JR1
Yang, RR1
Rippon, GA1
Lankford, DA1
Beck, J1
Hemmeter, U1
Brand, S1
Muheim, F1
Hatzinger, M1
Holsboer-Trachsler, E1
Black, W1
Hoey, P1
Mayze, T1
Youakim, JM1
Tiller, JM1
Abolfazli, R1
Hosseini, M1
Ghanizadeh, A1
Ghaleiha, A1
Tabrizi, M1
Raznahan, M1
Golalizadeh, M1
Akhondzadeh, S1
Howland, RH1
Videbech, P1
Markovitz, PJ1
Wagner, S1
Schillerstrom, JE1
Seaman, JS1
DeBattista, C5
Doghramji, K1
Menza, MA2
Rosenthal, MH1
Fieve, RR1
Lembke, A1
Solvason, HB2
Ghebremichael, R1
Poirier, J1
Even, C1
Friedman, S1
Dardennes, R1
Guelfi, JD1
Ninan, PT2
Hassman, HA1
Glass, SJ1
McManus, FC1
Clemons, WE1
Makela, E1
Young, J1
Thase, ME2
Price, CS1
Taylor, FB1
Arora, S1
Hughes, RJ1
Luborzewski, A1
Regen, F1
Schindler, F1
Anghelescu, I1
Block, J1
Baldwin, DS1
Papakostas, GI1
Berlim, MT1
Turecki, MG1
Dunlop, BW1
Crits-Christoph, P1
Evans, DL1
Hirschowitz, J1
Rickels, K1
Garlow, SJ1
Gallop, RJ1
Fountoulakis, KN1
Siamouli, M1
Panagiotidis, P1
Magiria, S1
Kantartzis, S1
Iacovides, A1
Kaprinis, GS1
Oulis, P1
Kouzoupis, AV1
Kontoangelos, K1
Pachou, E1
Masdrakis, VG1
Soldatos, CR1
Kaufman, KR1
Fitzsimmons, A1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder[NCT01072929]Phase 3433 participants (Actual)Interventional2010-01-31Completed
Improving Therapeutic Learning in Depression: Proof of Concept[NCT02376257]Phase 236 participants (Actual)Interventional2014-09-16Completed
Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder[NCT00518986]Phase 4249 participants (Actual)Interventional2007-10-31Completed
An 8 Week Double Blind, Placebo-Controlled, Parallel Group, Fixed Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder[NCT00481195]Phase 2257 participants (Actual)Interventional2007-06-30Completed
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640]Phase 1/Phase 2520 participants (Anticipated)Interventional2023-02-20Recruiting
Does Modafinil Have Pro-cognitive Effects in Those With Residual Cognitive Impairment Despite Remitted Depression?[NCT03620253]Phase 39 participants (Actual)Interventional2018-10-15Terminated (stopped due to Principal Investigator left study site)
Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979]Phase 435 participants (Actual)Interventional2010-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline to Endpoint in the Hamilton Anxiety Scale (HAM-A) Total Score

HAM-A measures the severity of anxiety symptoms. The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Negative change from baseline scores indicate a decrease in severity of anxiety. (NCT01072929)
Timeframe: Day 0 (baseline), last postbaseline observation (up to 8 weeks)

Interventionunits on a scale (Mean)
Placebo-4.2
Armodafinil 150 mg/Day-4.2
Armodafinil 200 mg/Day-3.3

Change From Baseline to Endpoint in the Insomnia Severity Index (ISI) Total Score

The ISI is a participant-rated, 7-item questionnaire designed to assess the severity of the participant's insomnia. Each item is ranked 0 (none) through 4 (very severe) and has a descriptor associated with each severity level. Total range is 0 (no insomnia) to 28 (very severe insomnia). Responses to each item are added to obtain a total score to determine the severity of insomnia. Negative change from baseline scores indicate a decrease in severity of insomnia. (NCT01072929)
Timeframe: Day 0 (baseline), last postbaseline observation (up to 8 weeks)

Interventionunits on a scale (Mean)
Placebo-6.4
Armodafinil 150 mg/Day-6.5
Armodafinil 200 mg/Day-5.6

Change From Baseline to Endpoint in the Young Mania Rating Scale (YMRS) Total Score

The YMRS is a clinician-rated, 11-item checklist used to measure the severity of manic episodes. Information for assigning scores is gained from the participant's subjective reported symptoms over the previous 48 hours and from clinical observation during the interview. Seven items are ranked 0 through 4 and have descriptors associated with each severity level. Four items (irritability, speech, content, and disruptive-aggressive behavior) are scored 0 through 8 and have descriptors for every second increment. The total scale is 0-60. A score of ≤12 indicates remission of manic symptoms, and higher scores indicate greater severity of mania. Negative change from baseline scores indicate a decrease in severity of mania. (NCT01072929)
Timeframe: Day 0 (baseline), last postbaseline observation (up to 8 weeks)

Interventionunits on a scale (Mean)
Placebo-1.1
Armodafinil 150 mg/Day-1.1
Armodafinil 200 mg/Day-1.0

Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)

"The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits.~Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression." (NCT01072929)
Timeframe: Day 0 (baseline), Week 8

Interventionunits on a scale (Least Squares Mean)
Placebo-17.9
Armodafinil 150 mg/Day-21.7
All Armodafinil-20.8

Change From Baseline to Different Treatment Weeks in the Clinical Global Impression of Severity (CGI-S) for Depression

The CGI-S is an observer-rated scale that measures illness severity on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). Negative change from baseline values indicate improvement in the severity of depression. (NCT01072929)
Timeframe: Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)

,,
Interventionunits on a scale (Mean)
Week 1 (191, 194, 29)Week 2 (188, 181, 28)Week 4 (178, 168, 27)Week 6 (160, 158, 21)Week 7 (152, 145, 19)Week 8 (155, 150, 24)Endpoint (196, 197, 31)
Armodafinil 150 mg/Day-0.4-0.6-0.9-1.4-1.6-1.7-1.4
Armodafinil 200 mg/Day-0.5-0.5-0.8-0.9-1.1-1.3-1.2
Placebo-0.3-0.5-0.9-1.2-1.3-1.5-1.3

Change From Baseline to Different Treatment Weeks in the Total Score From the 16-Item Quick Inventory of Depressive Symptomatology-Clinician-Rated (QIDS-C16)

The QIDS-C16 was derived from specified items in the IDS-C30, clinician-rated scale to assess the severity of a participant's depressive symptoms. Total scores range from 0-27, with a score of 0 indicating no depression and a score of 27 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression. (NCT01072929)
Timeframe: Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)

,,
Interventionunits on a scale (Mean)
Week 1 (191, 194, 29)Week 2 (188, 181, 27)Week 4 (178, 168, 27)Week 6 (160, 158, 21)Week 7 (152, 145, 19)Week 8 (155, 150, 24)Endpoint (196, 197, 31)
Armodafinil 150 mg/Day-2.8-4.4-6.5-8.1-8.6-9.4-8.0
Armodafinil 200 mg/Day-4.1-5.0-6.4-7.4-7.6-7.3-6.6
Placebo-2.3-3.8-5.6-6.9-7.2-7.6-6.6

Change From Baseline to Different Treatment Weeks in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)

"The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits.~Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression." (NCT01072929)
Timeframe: Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)

,,
Interventionunits on a scale (Mean)
Week 1 (191, 193, 29)Week 2 (188, 181, 27)Week 4 (178, 168, 27)Week 6 (160, 158, 21)Week 7 (152, 144, 19)Week 8 (155, 150, 24)Endpoint (196, 197, 31)
Armodafinil 150 mg/Day-6.5-10.4-15.6-19.7-21.7-23.3-20.2
Armodafinil 200 mg/Day-9.8-12.9-15.3-17.4-17.8-17.0-15.8
Placebo-6.1-10.2-14.3-18.3-18.8-19.7-17.3

Change From Baseline to Weeks 4, 8 and Endpoint in the Global Assessment for Functioning (GAF) Scale

The Global Assessment of Functioning (GAF) is a numeric scale (1 through 100) used by mental health clinicians and physicians to rate subjectively the social, occupational, and psychological functioning of adults, e.g., how well or adaptively one is meeting various problems-in-living. Ratings of 1 - 10 mean the participant is in persistent danger of severely hurting self or others (e.g., recurrent violence) or persistent inability to maintain minimal personal hygiene or serious suicidal act with clear expectation of death. Ratings of 91 - 100 indicate no symptoms, and the participant exhibits superior functioning in a wide range of activities, life's problems never seem to get out of hand, is sought out by others because of his or her many positive qualities. Positive change from baseline values indicate improvement in functioning. (NCT01072929)
Timeframe: Day 0 (baseline), Weeks 4, 8, and last postbaseline observation (up to 8 weeks)

,,
Interventionunits on a scale (Mean)
Week 4 (175, 168, 27)Week 8 (153, 150, 24)Endpoint (191, 189, 29)
Armodafinil 150 mg/Day7.715.612.8
Armodafinil 200 mg/Day8.913.612.2
Placebo7.211.410.2

Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Aborted Attempt Question

"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Behavior - Aborted Attempt question records whether the participant began to take steps toward making a suicide attempt but stops themselves before starting the potentially self-injurious act since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)

,,
Interventionparticipants (Number)
Week 1 (191, 194, 29)Week 2 (188, 181, 27)Week 4 (178, 168, 27)Week 6 (159, 158, 21)Week 7 (152, 145, 19)Week 8 (155, 150, 24)Endpoint (197, 198, 31)
Armodafinil 150 mg/Day0000000
Armodafinil 200 mg/Day0000000
Placebo0000000

Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Actual Attempt Question

The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation. The Suicidal Behavior - Actual Attempt question records whether the participant committed a potentially self-injurious act with at least some wish to die since the last visit. (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)

,,
Interventionparticipants (Number)
Week 1 (191, 194, 29)Week 2 (188, 181, 27)Week 4 (178, 168, 27)Week 6 (159, 158, 21)Week 7 (152, 145, 19)Week 8 (155, 150, 24)Endpoint (197, 198, 31)
Armodafinil 150 mg/Day0000000
Armodafinil 200 mg/Day0000000
Placebo0000001

Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Completed Suicide Question

"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Behavior - Completed Suicide question records whether the participant intentionally causing his/her's own death since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)

,,
Interventionparticipants (Number)
Week 1 (191, 194, 29)Week 2 (188, 181, 27)Week 4 (178, 168, 27)Week 6 (159, 158, 21)Week 7 (152, 145, 19)Week 8 (155, 150, 24)Endpoint (197, 198, 31)
Armodafinil 150 mg/Day0000000
Armodafinil 200 mg/Day0000000
Placebo0000000

Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Interrupted Attempt Question

"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Behavior - Interrupted Attempt question records whether the participant was interrupted by an outside circumstance from starting the potentially self-injurious act with at least some wish to die since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)

,,
Interventionparticipants (Number)
Week 1 (191, 194, 29)Week 2 (188, 181, 27)Week 4 (178, 168, 27)Week 6 (159, 158, 21)Week 7 (152, 145, 19)Week 8 (155, 150, 24)Endpoint (197, 198, 31)
Armodafinil 150 mg/Day0000000
Armodafinil 200 mg/Day0000000
Placebo0000000

Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Non-Suicidal Self-Injurious Behavior Question

"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Behavior - Non-Suicidal Self-Injurious Behavior question records whether the participant committed a potentially self-injurious act that was not associated with a wish to die since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)

,,
Interventionparticipants (Number)
Week 1 (191, 194, 29)Week 2 (188, 181, 27)Week 4 (178, 168, 27)Week 6 (159, 158, 21)Week 7 (152, 145, 19)Week 8 (155, 150, 24)Endpoint (197, 198, 31)
Armodafinil 150 mg/Day0000000
Armodafinil 200 mg/Day0000000
Placebo0000000

Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Preparatory Acts or Behavior Question

"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Behavior - Preparatory Acts or Behavior question records whether the participant exhibited acts or preparations towards imminently making a suicide attempt since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)

,,
Interventionparticipants (Number)
Week 1 (191, 194, 29)Week 2 (188, 181, 27)Week 4 (178, 168, 27)Week 6 (159, 158, 21)Week 7 (152, 145, 19)Week 8 (155, 150, 24)Endpoint (197, 198, 31)
Armodafinil 150 mg/Day0000000
Armodafinil 200 mg/Day0000000
Placebo0000001

Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Suicidal Behavior Question

"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Behavior - Suicidal Behavior question records whether in the clinician's opinion, the participant exhibited suicidal behavior since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)

,,
Interventionparticipants (Number)
Week 1 (191, 194, 29)Week 2 (188, 181, 27)Week 4 (178, 168, 27)Week 6 (159, 158, 21)Week 7 (152, 145, 19)Week 8 (155, 150, 24)Endpoint (197, 198, 31)
Armodafinil 150 mg/Day0000000
Armodafinil 200 mg/Day0000000
Placebo0000001

Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Any Methods (Not Plan) Without Intent to Act Question

"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Ideation - Any Methods (Not Plan) Without Intent to Act question records whether the participant endorses thoughts of suicide and has thought of at least one method but has no specific plan of action since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)

,,
Interventionparticipants (Number)
Week 1 (3, 6, 1)Week 2 (2, 2, 0)Week 4 (2, 4, 0)Week 6 (0, 2, 0)Week 7 (1, 0, 0)Week 8 (0, 2, 0)Endpoint (11, 11, 1)
Armodafinil 150 mg/Day0010003
Armodafinil 200 mg/Day0000000
Placebo1000001

Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Non-Specific Active Suicidal Thoughts Question

"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Ideation - Non-Specific Active Suicidal Thoughts question records whether the participant shares general non-specific thoughts of wanting to end one's life/commit suicide since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)

,,
Interventionparticipants (Number)
Week 1 (191, 194, 29)Week 2 (188, 181, 27)Week 4 (178, 168, 27)Week 6 (159, 158, 21)Week 7 (152, 145, 19)Week 8 (155, 150, 24)Endpoint (197, 198, 31)
Armodafinil 150 mg/Day1111003
Armodafinil 200 mg/Day1000000
Placebo1000000

Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Some Intent to Act Without a Specific Plan Question

"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Ideation - Some Intent to Act Without a Specific Plan question records whether the participant has active suicidal thoughts of killing oneself and reports having some intent to act on such thoughts since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)

,,
Interventionparticipants (Number)
Week 1 (3, 6, 1)Week 2 (2, 2, 0)Week 4 (2, 4, 0)Week 6 (0, 2, 0)Week 7 (1, 0, 0)Week 8 (0, 2, 0)Endpoint (11, 11, 1)
Armodafinil 150 mg/Day0000000
Armodafinil 200 mg/Day0000000
Placebo0000000

Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Specific Plan and Intent Question

"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Ideation - Specific Plan and Intent question records whether the participant has active suicidal thoughts of killing oneself with details of plan fully or partially worked out and the participant has some intent to carry out the plan since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)

,,
Interventionparticipants (Number)
Week 1 (3, 6, 1)Week 2 (2, 2, 0)Week 4 (2, 4, 0)Week 6 (0, 2, 0)Week 7 (1, 0, 0)Week 8 (0, 2, 0)Endpoint (11, 11, 1)
Armodafinil 150 mg/Day0000000
Armodafinil 200 mg/Day0000000
Placebo0000001

Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Wish to Be Dead Question

"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Ideation - Wish to Be Dead question records whether the participant endorses thoughts about a wish to dead or not alive anymore, or a wish to fall asleep and not wake up since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)

,,
Interventionparticipants (Number)
Week 1 (191, 194, 29)Week 2 (188, 181, 27)Week 4 (178, 168, 27)Week 6 (159, 158, 21)Week 7 (152, 145, 19)Week 8 (155, 150, 24)Endpoint (197, 198, 31)
Armodafinil 150 mg/Day7455027
Armodafinil 200 mg/Day1000000
Placebo4230116

Participants With Treatment-Emergent Adverse Events (TEAE)

"AEs were graded by the investigator for severity on a three-point scale: mild, moderate and severe. Causality is graded as either related or not related. A serious adverse event (SAE) is an AE resulting in death, a life-threatening adverse event, hospitalization, a persistent or significant disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may require medical intervention to prevent any of the previous results.~Protocol-defined adverse events requiring expedited reporting included skin rash, hypersensitivity reaction, emergent suicidal ideation or suicide attempt, and psychosis." (NCT01072929)
Timeframe: Day 1 to Week 9

,,
Interventionparticipants (Number)
>=1 adverse eventSevere adverse eventTreatment-related adverse eventDeathsOther serious adverse eventsWithdrawn from study due to adverse eventsProtocol-defined adverse events
Armodafinil 150 mg/Day9564403117
Armodafinil 200 mg/Day234131220
Placebo918440574

Percentage of Participants in Remission At Different Treatment Weeks According to the 30-Item Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) Total Score

"A participant in remission was defined as a participant with an IDS-C30 total score of 11 or less.~The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits.~Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)

,,
Interventionpercentage of participants (Number)
Week 1 (191, 193, 29)Week 2 (188, 181, 27)Week 4 (178, 168, 27)Week 6 (160, 158, 21)Week 7 (152, 144, 19)Week 8 (155, 150, 24)Endpoint (196, 197, 31)
Armodafinil 150 mg/Day12415172821
Armodafinil 200 mg/Day371110161713
Placebo12616222217

Percentage of Responders At Different Treatment Weeks According to the 30-Item Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) Total Score

"A responder is a participant with a ≥50% decrease or greater from baseline in the total score of the IDS-C30. The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits.~Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression." (NCT01072929)
Timeframe: Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)

,,
Interventionpercentage of participants (Number)
Week 1 (191, 193, 29)Week 2 (188, 181, 27)Week 4 (178, 168, 27)Week 6 (160, 158, 21)Week 7 (152, 144, 19)Week 8 (155, 150, 24)Endpoint (196, 197, 31)
Armodafinil 150 mg/Day682639515546
Armodafinil 200 mg/Day10263743474239
Placebo4122338393934

1 Week Delayed Recall Logical Memory

Higher scores reflect greater recall of Wechsler Memory Scale (WMS) Story B content assessed one week after last rehearsal. Possible scores range from 0 to 25. (NCT02376257)
Timeframe: Week 2 and Week 3

,,
Interventionunits on a scale (Mean)
Week 2Week 3
100 mg Modafinil4.412.8
250 mg DCS1.89.5
Placebo5.013.6

1 Week Delayed Recall of Emotional Story Items

1 Week Delayed Recall of a Threat-Related Story. Scores can range from 0 to 74, with higher scores reflect greater memory for story items. (NCT02376257)
Timeframe: Week 2 and Week 3

,,
Interventionunits on a scale (Mean)
Week 2Week 3
100 mg Modafinil21.337.3
250 mg DCS13.525.0
Placebo16.126.4

Digits Backward

The examiner reads a list of digits and asks that each digit be read backwards. The score is the total number of trials completed correctly; scores range from 0 to 16. Higher scores indicate better performance. (NCT02376257)
Timeframe: Baseline, Week 1, Week 2, Week 3

,,
InterventionNumber of correct trials (Mean)
BaselineWeek 1Week 2Week 3
100 mg Modafinil9.510.411.311.4
250 mg DCS8.39.2510.09.6
Placebo11.312.212.111.7

Immediate Memory Measured by the Hopkins Verbal Learning Task

The Hopkins Verbal Learning Test (HVLT) consists of a 12-item word list, composed of four words from each of the three semantic categories. The patient's free recall of the list is recorded. The same procedure is repeated for two more trials. The total recall score for the third trial was used as the recorded score and ranged from a minimum of zero to a maximum of 12 correct answers. (NCT02376257)
Timeframe: Baseline, Week 1, Week 2, Week 3

,,
InterventionNumber of words recalled (Mean)
BaselineWeek 1Week 2Week 3
100 mg Modafinil9.69.99.710.1
250 mg DCS8.57.88.78.8
Placebo9.69.49.69.4

Immediate Recall of Emotional Story Items

Immediate recall score of items from the Emotional Story presentation. Scores can range from 0 to 74, with higher scores reflect greater memory for story items. (NCT02376257)
Timeframe: Week 1, Week 2, Week 3

,,
InterventionNumber of story units recalled (Mean)
Week 1Week 2Week 3
100 mg Modafinil35.246.849.9
250 mg DCS22.434.438.4
Placebo32.235.543.4

Logical Memory Immediate Recall

Immediate Story Recall from the Wechsler Memory Scale Story B. Higher scores reflect greater recall of the story material from the previous week. Possible scores range from 0 to 25. (NCT02376257)
Timeframe: Week 1, Week 2, Week 3

,,
InterventionNumber of story units recalled (Mean)
Week 1Week 2Week 3
100 mg Modafinil17.117.821.5
250 mg DCS14.817.718.5
Placebo16.218.221.2

Recall of Cognitive Therapy Content

A modified Cognitive Therapy Awareness Scale (CTAS) was used to assess delayed memory for cognitive therapy content from the computerized CBT. Higher scores indicate better memory for CBT skills. Scores range from 0 to 40. (NCT02376257)
Timeframe: Week 2 and Week 3

,,
InterventionNumber of correct units of information (Mean)
Week 2Week 3
100 mg Modafinil26.829.7
250 mg DCS25.428.2
Placebo24.728.7

Skills of Cognitive Therapy

This measure assesses the self-reported use of skills from cognitive therapy. Scores can range from 8 to 40, and higher scores indicate greater use. (NCT02376257)
Timeframe: Week 2 and Week 3

,,
Interventionunits on a scale (Mean)
Week 2Week 3
100 mg Modafinil20.524.3
250 mg DCS23.326.4
Placebo24.825.7

Change From Baseline in the Excessive Sleepiness (ES) Symptom Rating Form - Sleepiness Scores at 12 Weeks

"Cephalon created the Excessive Sleepiness Symptom Rating Form to assess symptoms of excessive sleepiness. Patients rate 7 symptoms(Tiredness, Fatigue, Sleepiness, Lack of energy, Trouble paying attention, Forgetfulness, Trouble staying organized) each on an 11-point Likert scale(0=no problem at all 10=as bad as you can imagine). ES Symptom Rating Form was designed to follow the response to treatment (measuring severity) of each of these 7 symptoms using the same 11-point scale. Change from Baseline to 12 Weeks is presented only for the symptom of Sleepiness." (NCT00518986)
Timeframe: Baseline and 12 weeks following start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-2.2
Placebo-1.3

Change From Baseline in the Excessive Sleepiness (ES) Symptom Rating Form - Sleepiness Scores at 2 Weeks

"Cephalon created the Excessive Sleepiness Symptom Rating Form to assess symptoms of excessive sleepiness. Patients rate 7 symptoms(Tiredness, Fatigue, Sleepiness, Lack of energy, Trouble paying attention, Forgetfulness, Trouble staying organized) each on an 11-point Likert scale(0=no problem at all 10=as bad as you can imagine). ES Symptom Rating Form was designed to follow the response to treatment (measuring severity) of each of these 7 symptoms using the same 11-point scale. Change from Baseline to 2 Weeks is presented only for the symptom of Sleepiness." (NCT00518986)
Timeframe: Baseline and 2 weeks

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-1.6
Placebo-1.2

Change From Baseline in the Excessive Sleepiness (ES) Symptom Rating Form - Sleepiness Scores at 4 Weeks

"Cephalon created the Excessive Sleepiness Symptom Rating Form to assess symptoms of excessive sleepiness. Patients rate 7 symptoms(Tiredness, Fatigue, Sleepiness, Lack of energy, Trouble paying attention, Forgetfulness, Trouble staying organized) each on an 11-point Likert scale(0=no problem at all 10=as bad as you can imagine). ES Symptom Rating Form was designed to follow the response to treatment (measuring severity) of each of these 7 symptoms using the same 11-point scale. Change from Baseline to 4 Weeks is presented only for the symptom of Sleepiness." (NCT00518986)
Timeframe: Baseline and 4 weeks following start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-2.1
Placebo-1.1

Change From Baseline in the Excessive Sleepiness (ES) Symptom Rating Form - Sleepiness Scores at 8 Weeks

"Cephalon created the Excessive Sleepiness Symptom Rating Form to assess symptoms of excessive sleepiness. Patients rate 7 symptoms(Tiredness, Fatigue, Sleepiness, Lack of energy, Trouble paying attention, Forgetfulness, Trouble staying organized) each on an 11-point Likert scale(0=no problem at all 10=as bad as you can imagine). ES Symptom Rating Form was designed to follow the response to treatment (measuring severity) of each of these 7 symptoms using the same 11-point scale. Change from Baseline to 8 Weeks is presented only for the symptom of Sleepiness." (NCT00518986)
Timeframe: baseline and 8 weeks following start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-1.8
Placebo-0.9

Change From Baseline in the Excessive Sleepiness (ES) Symptom Rating Form - Sleepiness Scores at Endpoint (12 Weeks or Last Observation After Baseline)

"The Excessive Sleepiness Symptom Rating Form was used to assess symptoms of excessive sleepiness. Patients rate 7 symptoms(tiredness, fatigue, sleepiness, lack of energy, trouble paying attention, forgetfulness, trouble staying organized) on an 11-point Likert scale (0 = no problem at all to 10 = as bad as you can imagine). ES Symptom Rating Form was designed to follow the response to treatment measuring severity of each of these 7 symptoms using the same 11-point scale. Change from Baseline to Endpoint (12 weeks or last baseline observation) is presented only for the symptom of Sleepiness." (NCT00518986)
Timeframe: Baseline and Endpoint (12 weeks or last observation after baseline)

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-1.8
Placebo-1.4

Change From Baseline on Brief Fatigue Inventory (BFI) Interference Score at 12 Weeks (or Last Observation After Baseline)

The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The Interference Score consists of 6 questions that ask subjects to rate on a 0 to 10 scale how during the past 24 hours fatigue has interfered with their general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. The scores are averaged (0-10) for the Interference Score. (NCT00518986)
Timeframe: Baseline and 12 weeks after start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-1.1
Placebo-0.3

Change From Baseline on Brief Fatigue Inventory (BFI) Interference Score at 2 Weeks

The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The Interference Score consists of 6 questions that ask subjects to rate on a 0 to 10 scale how during the past 24 hours fatigue has interfered with their general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. The scores are averaged (0-10) for the Interference Score. (NCT00518986)
Timeframe: Baseline and 2 weeks after start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-0.6
Placebo0.0

Change From Baseline on Brief Fatigue Inventory (BFI) Interference Score at 4 Weeks

The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The Interference Score consists of 6 questions that ask subjects to rate on a 0 to 10 scale how during the past 24 hours fatigue has interfered with their general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. The scores are averaged (0-10) for the Interference Score. (NCT00518986)
Timeframe: Baseline and 4 weeks after start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-1.0
Placebo-0.6

Change From Baseline on Brief Fatigue Inventory (BFI) Interference Score at 8 Weeks

The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The Interference Score consists of 6 questions that ask subjects to rate on a 0 to 10 scale how during the past 24 hours fatigue has interfered with their general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. The scores are averaged (0-10) for the Interference Score. (NCT00518986)
Timeframe: Baseline and 8 weeks after start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-0.9
Placebo-0.2

Change From Baseline on Brief Fatigue Inventory (BFI) Interference Score at Endpoint (12 Weeks or Last Observation After Baseline)

The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The Interference Score consists of 6 questions that ask subjects to rate on a 0 to 10 scale how during the past 24 hours fatigue has interfered with their general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. The scores are averaged (0-10) for the Interference Score. (NCT00518986)
Timeframe: Baseline and at endpoint (12 weeks or last observation after baseline)

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-0.9
Placebo-0.3

Change From Baseline on Brief Fatigue Inventory (BFI) Total Score at 12 Weeks

The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The total score is calculated by taking the sum of all 9 rating scales for a minimum score of 0 and a maximum score of 90. This assessment examines the difference in total BFI score from Baseline to 12 weeks. (NCT00518986)
Timeframe: Baseline and 12 weeks after start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-10.5
Placebo-3.3

Change From Baseline on Brief Fatigue Inventory (BFI) Total Score at 2 Weeks

The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The total score is calculated by taking the sum of all 9 rating scales for a minimum score of 0 and a maximum score of 90. This assessment examines the difference in total BFI score from Baseline to 2 weeks. (NCT00518986)
Timeframe: Baseline and 2 weeks after start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-6.1
Placebo-0.9

Change From Baseline on Brief Fatigue Inventory (BFI) Total Score at 4 Weeks

The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The total score is calculated by taking the sum of all 9 rating scales for a minimum score of 0 and a maximum score of 90. This assessment examines the difference in total BFI score from Baseline to 4 weeks. (NCT00518986)
Timeframe: Baseline and 4 weeks after start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-9.5
Placebo-5.8

Change From Baseline on Brief Fatigue Inventory (BFI) Total Score at 8 Weeks

The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The total score is calculated by taking the sum of all 9 rating scales for a minimum score of 0 and a maximum score of 90. This assessment examines the difference in total BFI score from Baseline to 8 weeks. (NCT00518986)
Timeframe: Baseline and 8 weeks after start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-8.8
Placebo-3.0

Change From Baseline on Brief Fatigue Inventory (BFI) Worse Daily Fatigue Score at 12 Weeks

The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. This measure compares the change in score from baseline to Week 12. (NCT00518986)
Timeframe: 12 weeks

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-1.4
Placebo-0.6

Change From Baseline on Brief Fatigue Inventory (BFI) Worse Daily Fatigue Score at 2 Weeks

The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. This measure compares the change in score from baseline to Week 2. (NCT00518986)
Timeframe: Baseline and 2 weeks after start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-1.1
Placebo-0.2

Change From Baseline on Brief Fatigue Inventory (BFI) Worse Daily Fatigue Score at 4 Weeks

The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. This measure compares the change in score from baseline to Week 4. (NCT00518986)
Timeframe: Baseline and 4 weeks after start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-1.2
Placebo-0.8

Change From Baseline on Brief Fatigue Inventory (BFI) Worse Daily Fatigue Score at 8 Weeks

The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. This measure compares the change in score from baseline to Week 8. (NCT00518986)
Timeframe: Baseline and 8 weeks after start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-1.2
Placebo-0.3

Change From Baseline on Epworth Sleepiness Scale (ESS) at 12 Weeks

ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The change in ESS total score from baseline to 12 weeks are summarized. (NCT00518986)
Timeframe: 12 weeks (or last observation after baseline)

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-6.8
Placebo-4.8

Change From Baseline on Epworth Sleepiness Scale (ESS) at 2 Weeks

ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The change in ESS total score from baseline to two weeks are summarized. (NCT00518986)
Timeframe: Baseline and 2 weeks following start of study drug administration

InterventionUnit on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-4.8
Placebo-3.8

Change From Baseline on Epworth Sleepiness Scale (ESS) at 4 Weeks

ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The change in ESS total score from baseline to 4 weeks are summarized. (NCT00518986)
Timeframe: Baseline and 4 weeks after start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-5.5
Placebo-4.2

Change From Baseline on Epworth Sleepiness Scale (ESS) at 8 Weeks

ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The change in ESS total score from baseline to 8 weeks are summarized. (NCT00518986)
Timeframe: Baseline and 8 weeks after start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-6.0
Placebo-4.8

Change From Baseline on Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score at 12 Weeks

The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum = 2 maximum = 120) was calculated from the responses. The change in total score from baseline to 12 weeks is presented here. (NCT00518986)
Timeframe: baseline and 12 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day2.6
Placebo1.6

Change From Baseline on Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score at 2 Weeks

The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum = 2 maximum = 120) was calculated from the responses. The change in total score from baseline to 2 weeks is presented here. (NCT00518986)
Timeframe: baseline and 2 weeks following start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day1.7
Placebo1.1

Change From Baseline on Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score at 4 Weeks

The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum = 2 maximum = 120) was calculated from the responses. The change in total score from baseline to 4 weeks is presented here. (NCT00518986)
Timeframe: baseline and 4 weeks following start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day2.2
Placebo1.4

Change From Baseline on Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score at 8 Weeks

The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum = 2 maximum = 120) was calculated from the responses. The change in total score from baseline to 8 weeks is presented here. (NCT00518986)
Timeframe: baseline and 8 weeks following start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day2.2
Placebo1.4

Change From Baseline on Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score at Endpoint (12 Weeks or Last Observation After Baseline)

The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum of 2 maximum of 120) was calculated from the responses. The change in total score from baseline to Endpoint (12 weeks or last observation after baseline) is presented here. (NCT00518986)
Timeframe: Baseline and endpoint (12 weeks after start of study drug or last observation after baseline)

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day2.3
Placebo1.5

Change From Baseline on Maintenance of Wakefulness Test (MWT) at 12 Weeks

MWT measures ability of subject to remain awake. Subjects instructed to try and remain awake during series of four 30-minute periods (0900, 1100, 1300, and 1500) reclining in dark room. Each period was terminated immediately after sleep onset or at end of 30 minutes if no sleep occured. If subject fell asleep, they were awakened and not allowed to sleep for remainder of that 30 minute period. Change from Baseline to 12 weeks in mean sleep latency (measured in minutes)averaged from each of the four testing intervals was measured. The poorest outcome was 0 minutes the best was 30 minutes. (NCT00518986)
Timeframe: baseline and 12 weeks (or last observation after baseline)

InterventionMinutes (Least Squares Mean)
Armodafinil 200 mg/Day2.5
Placebo1.4

Change From Baseline on Maintenance of Wakefulness Test (MWT) at 4 Weeks

MWT measures ability of subject to remain awake. Subjects instructed to try and remain awake during series of four 30-minute periods (0900, 1100, 1300, and 1500) reclining in dark room. Each period was terminated immediately after sleep onset or at end of 30 minutes if no sleep occured. If subject fell asleep, they were awakened and not allowed to sleep for remainder of that 30 minute period. Change from Baseline to 4 weeks in mean sleep latency (measured in minutes)averaged from each of the four testing intervals was measured. The poorest outcome was 0 minutes the best was 30 minutes. (NCT00518986)
Timeframe: baseline and 4 weeks

InterventionMinutes (Least Squares Mean)
Armodafinil 200 mg/Day2.7
Placebo-0.1

Change From Baseline on Maintenance of Wakefulness Test (MWT) at 8 Weeks

MWT measures ability of subject to remain awake. Subjects instructed to try and remain awake during series of four 30-minute periods (0900, 1100, 1300, and 1500) reclining in dark room. Each period was terminated immediately after sleep onset or at end of 30 minutes if no sleep occured. If subject fell asleep, they were awakened and not allowed to sleep for remainder of that 30 minute period. Change from Baseline to 8 weeks in mean sleep latency (measured in minutes)averaged from each of the four testing intervals was measured. The poorest outcome was 0 minutes the best was 30 minutes. (NCT00518986)
Timeframe: Baseline and 8 weeks following start of study drug administration

InterventionMinutes (Least Squares Mean)
Armodafinil 200 mg/Day2.1
Placebo1.2

Change From Baseline on Maintenance of Wakefulness Test (MWT) to Endpoint (12 Weeks or Last Observation After Baseline)

MWT measures ability of subject to remain awake. Subjects instructed to try and remain awake during series of 4 30-minute periods (0900, 1100, 1300, and 1500) reclining in dark room. Each period was terminated immediately after sleep onset or at end of 30 minutes if no sleep occurred. If subject fell asleep, they were awakened and not allowed to sleep for remainder of that 30 minute period. Change from Baseline to Endpoint (12 weeks or last observation after baseline) in mean sleep latency averaged from the 4 intervals was measured. Poorest outcome was 0 minutes the best was 30 minutes. (NCT00518986)
Timeframe: Baseline and 12 weeks (or last observation after baseline)

InterventionMinutes (Mean)
Armodafinil 200 mg/Day2.6
Placebo1.1

Change From Baseline on Medical Outcomes Study 6 Item Cognitive Functioning (MOS-CF6) Scale at 12 Weeks

"The MOS-CF6 assesses self-reported cognitive function. Items were selected to cover 6 relevant aspects of cognitive functioning as follows: confusion, concentration/thinking, attention, memory, reasoning, problem-solving, and processing speed. The MOS-CF6 responses includes 6 choices, ranging from none of the time to all of the time. The MOS-CF6 is scored by summing responses across the 6 items and converting the total to a 0 - 100 point scale, with the higher score indicating better cognitive functioning. Data is presented showing the change in score from baseline to 12 weeks." (NCT00518986)
Timeframe: baseline and 12 weeks following start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day3.3
Placebo2.4

Change From Baseline on Medical Outcomes Study 6 Item Cognitive Functioning (MOS-CF6) Scale at 2 Weeks

"The MOS-CF6 assesses self-reported cognitive function. Items were selected to cover 6 relevant aspects of cognitive functioning as follows: confusion, concentration/thinking, attention, memory, reasoning, problem-solving, and processing speed. The MOS-CF6 responses includes 6 choices, ranging from none of the time to all of the time. The MOS-CF6 is scored by summing responses across the 6 items and converting the total to a 0 - 100 point scale, with the higher score indicating better cognitive functioning. Data is presented showing the change in score from baseline to 2 weeks." (NCT00518986)
Timeframe: baseline and 2 weeks

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day2.0
Placebo1.9

Change From Baseline on Medical Outcomes Study 6 Item Cognitive Functioning (MOS-CF6) Scale at 4 Weeks

"The MOS-CF6 assesses self-reported cognitive function. Items were selected to cover 6 relevant aspects of cognitive functioning as follows: confusion, concentration/thinking, attention, memory, reasoning, problem-solving, and processing speed. The MOS-CF6 responses includes 6 choices, ranging from none of the time to all of the time. The MOS-CF6 is scored by summing responses across the 6 items and converting the total to a 0 - 100 point scale, with the higher score indicating better cognitive functioning. Data is presented showing the change in score from baseline to 4 weeks." (NCT00518986)
Timeframe: baseline and 4 weeks following start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day3.4
Placebo2.4

Change From Baseline on Medical Outcomes Study 6 Item Cognitive Functioning (MOS-CF6) Scale at 8 Weeks

"The MOS-CF6 assesses self-reported cognitive function. Items were selected to cover 6 relevant aspects of cognitive functioning as follows: confusion, concentration/thinking, attention, memory, reasoning, problem-solving, and processing speed. The MOS-CF6 responses includes 6 choices, ranging from none of the time to all of the time. The MOS-CF6 is scored by summing responses across the 6 items and converting the total to a 0 - 100 point scale, with the higher score indicating better cognitive functioning. Data is presented showing the change in score from baseline to 8 weeks." (NCT00518986)
Timeframe: baseline and 8 weeks following start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day3.3
Placebo2.1

Change From Baseline on Medical Outcomes Study 6 Item Cognitive Functioning (MOS-CF6) Scale at Endpoint (12 Weeks or Last Observation After Baseline)

"The MOS-CF6 assesses self-reported cognitive function. Items were selected to cover 6 relevant aspects of cognitive functioning:confusion, concentration/thinking, attention, memory, reasoning, problem-solving, and processing speed. Responses range from none of the time to all of the time. The MOS-CF6 is scored by summing responses across the 6 items and converting the total to a 0 - 100 point scale, with the higher score indicating better cognitive functioning. Data is presented showing the change in score from baseline to Endpoint (12 weeks or last observation after baseline)." (NCT00518986)
Timeframe: Baseline and Endpoint (12 weeks or last observation after baseline)

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day3.2
Placebo2.4

Change From Baseline on the Brief Fatigue Inventory (BFI) Worst Daily Fatigue Score at Endpoint (12 Weeks or Last Observation After Baseline)

The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with >= 7 indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. This measure compares the change in score from baseline to Week 12 (or last observation after baseline). (NCT00518986)
Timeframe: Baseline and 12 weeks or last observation after baseline

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-1.3
Placebo-0.7

Change From Baseline on the Epworth Sleepiness Scale (ESS) at Endpoint (12 Weeks or Last Measurement After Baseline)

For this key secondary outcome the ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The change in ESS total score from baseline to Endpoint (12 weeks or last observation after baseline) are summarized. (NCT00518986)
Timeframe: Baseline and 12 weeks (or last observation after baseline)

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-6.5
Placebo-4.6

Change From Baseline to Endpoint (Week 12 or Last Observation After Baseline) in the Brief Fatigue Inventory (BFI) Total Score

The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The total score is calculated by taking the sum of all 9 rating scales for a minimum score of 0 and a maximum score of 90. This assessment examines the difference in total BFI score from Baseline to 12 weeks or last observation after baseline. (NCT00518986)
Timeframe: Baseline and 12 weeks following start of study drug administration or last recorded observation

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 200 mg/Day-8.9
Placebo-3.8

Clinical Global Impression of Change (CGI C) at 4 Weeks - Full Scale

The CGI-C is a clinician's rating of disease severity compared with baseline as assessed by Clinical Global Impression of Severity (CGI-S). CGI-C rates 7 responses: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. CGI-S measured 7 categories as well: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, among most extremely ill. The results for the number of participants who responded to each item on the full scale at 4 weeks are presented. (NCT00518986)
Timeframe: 4 weeks after start of treatment

,
InterventionParticipants (Number)
Very much improvedMuch improvedMinimally improvedNo changeMinimally worseMuch worseVery much worse
Armodafinil 200 mg/Day15342632310
Placebo11213237520

Clinical Global Impression of Change (CGI-C) at 12 Weeks

The CGI-C is a clinician's rating of disease severity compared with baseline as assessed by Clinical Global Impression of Severity (CGI-S). CGI-C rates 7 responses: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. CGI-S measured 7 categories as well: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, among most extremely ill. Proportion of responders who had at least minimal improvement in CGI-C ratings (as related to sleepiness) were assessed. (NCT00518986)
Timeframe: 12 weeks after beginning treatment

,
InterventionParticipants (Number)
At least minimal improvementNo improvement
Armodafinil 200 mg/Day6927
Placebo5342

Clinical Global Impression of Change (CGI-C) at 12 Weeks - Full Scale

The CGI-C is a clinician's rating of disease severity compared with baseline as assessed by Clinical Global Impression of Severity (CGI-S). CGI-C rates 7 responses: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. CGI-S measured 7 categories as well: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, among most extremely ill. The results for the number of participants who responded to each item on the full scale at 12 weeks are presented. (NCT00518986)
Timeframe: 12 weeks after starting study drug treatment

,
InterventionParticipants (Number)
Very much improvedMuch improvedMinimally improvedNo changeMinimally worseMuch worseVery much worse
Armodafinil 200 mg/Day27202222410
Placebo11222034710

Clinical Global Impression of Change (CGI-C) at 4 Weeks

"The CGI-C is a clinician's rating of disease severity compared with baseline as assessed by Clinical Global Impression of Severity (CGI-S). CGI-C rates 7 responses: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. CGI-S measured 7 categories as well: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, among most extremely ill. Proportion of responders who had at least minimally improved in CGI-C ratings (as related to sleepiness) at 4 weeks were assessed." (NCT00518986)
Timeframe: 4 weeks after beginning study drug treatment

,
InterventionParticipants (Number)
At least minimal improvementNo improvement
Armodafinil 200 mg/Day7536
Placebo6444

Clinical Global Impression of Change (CGI-C) at 8 Weeks

"The CGI-C is a clinician's rating of disease severity compared with baseline as assessed by Clinical Global Impression of Severity (CGI-S). CGI-C rates 7 responses: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. CGI-S measured 7 categories as well: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, among most extremely ill. Proportion of responders who had at least minimally improved in CGI-C ratings (as related to sleepiness) at 8 weeks were assessed." (NCT00518986)
Timeframe: 8 weeks after beginning study drug treatment

,
InterventionParticipants (Number)
At least minimal improvementNo improvement
Armodafinil 200 mg/Day7628
Placebo5246

Clinical Global Impression of Change (CGI-C) at 8 Weeks - Full Scale

The CGI-C is a clinician's rating of disease severity compared with baseline as assessed by Clinical Global Impression of Severity (CGI-S). CGI-C rates 7 responses: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. CGI-S measured 7 categories as well: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, among most extremely ill. The results for the number of participants who responded to each item on the full scale at 8 weeks are presented. (NCT00518986)
Timeframe: 8 weeks after start of study drug treatment

,
InterventionParticipants (Number)
Very much improvedMuch improvedMinimally improvedNo changeMinimally worseMuch worseVery much worse
Armodafinil 200 mg/Day16392126110
Placebo11192237720

Clinical Global Impression of Change (CGI-C) at Endpoint (12-weeks or Last Observation After Baseline)

"The CGI-C is a clinician's rating of disease severity compared with baseline as assessed by Clinical Global Impression of Severity (CGI-S). CGI-C rates improvement by 7 categories: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. CGI-S measured 7 categories of illness as well: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, among most extremely ill. Proportion of responders who had at least minimally improved in CGI-C ratings (as related to sleepiness) were assessed." (NCT00518986)
Timeframe: 12 weeks (or last observation after baseline)

,
InterventionParticipants (Number)
At least minimal improvementNo improvement
Armodafinil 200 mg/Day7835
Placebo5953

Number of Responders According to Brief Fatigue Inventory (BFI) Worst Fatigue Score at Endpoint (12 Weeks or Last Observation After Baseline)

The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. Subjects were considered responders if the final Worst Fatigue Score was < 7 at Week 12 or last observation after baseline. (NCT00518986)
Timeframe: 12 weeks after start of study drug administration (or last observation after baseline)

,
InterventionParticipants (Number)
RespondersNon-responders
Armodafinil 200 mg/Day6349
Placebo5655

Number of Responders According to the Brief Fatigue Inventory (BFI) Worst Fatigue Score at 12 Weeks

The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. Subjects were considered responders if the final Worst Fatigue Score was < 7 at Week 12. (NCT00518986)
Timeframe: 12 weeks after start of study drug administration

,
InterventionParticipants (Number)
RespondersNon-responders
Armodafinil 200 mg/Day5541
Placebo4847

Number of Responders According to the Brief Fatigue Inventory (BFI) Worst Fatigue Score at 2 Weeks

The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. Subjects were considered responders if the final Worst Fatigue Score was < 7 at Week 2. (NCT00518986)
Timeframe: 2 weeks after start of study drug administration

,
InterventionParticipants (Number)
RespondersNon-responders
Armodafinil 200 mg/Day6248
Placebo4365

Number of Responders According to the Brief Fatigue Inventory (BFI) Worst Fatigue Score at 4 Weeks

The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. Subjects were considered responders if the final Worst Fatigue Score was < 7 at Week 4. (NCT00518986)
Timeframe: 4 weeks after start of study drug administration

,
InterventionParticipants (Number)
RespondersNon-responders
Armodafinil 200 mg/Day6249
Placebo5751

Number of Responders According to the Brief Fatigue Inventory (BFI) Worst Fatigue Score at 8 Weeks

The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. Subjects were considered responders if the final Worst Fatigue Score was < 7 at Week 8. (NCT00518986)
Timeframe: 8 weeks after start of study drug administration

,
InterventionParticipants (Number)
RespondersNon-responders
Armodafinil 200 mg/Day6341
Placebo4256

Number of Responders According to the Epworth Sleepiness Scale (ESS) Total Score at 12 Weeks

ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The number of responders who had a total ESS score < 10 and the number of non-responders with a total score >= 10 at 12 weeks are presented. (NCT00518986)
Timeframe: 12 weeks

,
InterventionParticipants (Number)
RespondersNon-responders
Armodafinil 200 mg/Day6531
Placebo4748

Number of Responders According to the Epworth Sleepiness Scale (ESS) Total Score at 2 Weeks

ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The number of responders who had a total ESS score < 10 and the number of non-responders with a total score >= 10 at 2 weeks are presented. (NCT00518986)
Timeframe: 2 weeks

,
InterventionParticipants (Number)
RespondersNon-responders
Armodafinil 200 mg/Day5453
Placebo4064

Number of Responders According to the Epworth Sleepiness Scale (ESS) Total Score at 4 Weeks

ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The number of responders who had a total ESS score < 10 and the number of non-responders with a total score >= 10 at 4 weeks are presented. (NCT00518986)
Timeframe: 4 weeks

,
InterventionParticipants (Number)
RespondersNon-responders
Armodafinil 200 mg/Day5952
Placebo4563

Number of Responders According to the Epworth Sleepiness Scale (ESS) Total Score at 8 Weeks

ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The number of responders who had a total ESS score < 10 and the number of non-responders with a total score >= 10 at 8 weeks are presented. (NCT00518986)
Timeframe: 8 weeks

,
InterventionParticipants (Number)
RespondersNon-responders
Armodafinil 200 mg/Day6439
Placebo4751

Number of Responders According to the Functional Outcomes of Sleep Questionnaire (FOSQ) at Week 12

The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum = 2 maximum = 120) was calculated from the responses. A responder analysis defining responders as patients with a total score > 17.9 at 12 weeks is presented here. (NCT00518986)
Timeframe: 12 weeks following the start of study drug administration

,
InterventionParticipants (Number)
RespondersNon-responders
Armodafinil 200 mg/Day4351
Placebo2866

Number of Responders According to the Functional Outcomes of Sleep Questionnaire (FOSQ) at Week 4

The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum=2 maximum = 120) was calculated from the responses. A responder analysis defining responders as patients with a total score > 17.9 at 4 weeks is presented here. (NCT00518986)
Timeframe: 4 weeks following start of study drug administration

,
InterventionParticipants (Number)
RespondersNon-responders
Armodafinil 200 mg/Day4560
Placebo2479

Number of Responders According to the Functional Outcomes of Sleep Questionnaire (FOSQ) at Week 8

The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score was calculated from the responses (minimum = 2 maximum = 120). A responder analysis defining responders as patients with a total score > 17.9 at 8 weeks is presented here. (NCT00518986)
Timeframe: 8 weeks following start of study drug administration

,
InterventionParticipants (Number)
RespondersNon-responders
Armodafinil 200 mg/Day3665
Placebo2077

Number of Responders According to the Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score at 2 Weeks

The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum=2 maximum=120) was calculated from the responses. A responder analysis defining responders as patients with a total score > 17.9 at 2 weeks is presented here. (NCT00518986)
Timeframe: 2 weeks following start of study drug administration

,
InterventionParticipants (Number)
RespondersNon-responders
Armodafinil 200 mg/Day3075
Placebo1984

Number of Responders According to the Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score at Endpoint (Week 12 or Last Observation After Baseline)

The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum = 2 maximum = 120) was calculated from the responses. A responder analysis defining responders as patients with a total score > 17.9 at Endpoint (12 weeks or last observation after baseline) is presented. (NCT00518986)
Timeframe: Endpoint (week 12 or last observation after baseline)

,
InterventionParticipants (Number)
RespondersNon-responders
Armodafinil 200 mg/Day4961
Placebo3078

Change From Baseline to 4 Weeks in the Hamilton Anxiety Scale (HAM A) Total Score

The HAM-A is a clinician-rated 14 item scale that provides an overall measure of global anxiety, including psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety) symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0 - 56, where less than 17 indicates mild anxiety, 18 - 24 mild to moderate anxiety and 25-30 moderate to severe. The data presented here summarizes the change in HAM-A score from Baseline to 4 Weeks (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-3.6
Placebo-3.5

Change From Baseline to 8 Weeks in the Hamilton Anxiety Scale (HAM A) Total Score

The HAM-A is a clinician-rated 14 item scale that provides an overall measure of global anxiety, including psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety) symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0 - 56, where less than 17 indicates mild anxiety, 18 - 24 mild to moderate anxiety and 25-30 moderate to severe. The data presented here summarizes the change in HAM-A score from Baseline to 8 Weeks (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-4.7
Placebo-4.4

Change From Baseline to Endpoint (8 Weeks or Last Observation After Baseline) in Hamilton Anxiety Scale (HAM-A) Total Score

The HAM-A is a clinician-rated 14 item scale that provides an overall measure of global anxiety, including psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety) symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0 - 56, where less than 17 indicates mild anxiety, 18 - 24 mild to moderate anxiety, 25-30 moderate to severe, >30 very severe. The data presented here summarizes the change in HAM-A score from Baseline to Endpoint (8 weeks or last observation after baseline). (NCT00481195)
Timeframe: baseline and 8 weeks (or last observation after baseline)

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-4.1
Placebo-3.9

Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is a 10-item scale to evaluate the overall severity of a patient's depressive symptoms, that is completed by the physician. The rating scale makes use of both observational clues as to the subject's level of depression (eg. apparent sadness) and verbal indicators of depression expressed by the patient. Each of the 10 items is graded on a 6-point scale with anchors at 2 point intervals. Total scores range from 0 to 60, with the higher number indicating more severe symptoms of depression. Here we present data summarizing the change in MADRS from Baseline to Endpoint. (NCT00481195)
Timeframe: Baseline and Endpoint (8 weeks following the start of study drug administration or last observation after baseline)

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-12.3
Placebo-10.2

Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) in the Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)

The Q-LES-Q-SF is an instrument designed to measure general activities of daily living. It is a patient-rated quality of life questionnaire and consists of 16 items, but only the first 14 are included in the total score. Each item is rated by the patient on a scale from 1 - 5 (1=very poor, 2=poor, 3=fair, 4=good, and 5=very good). The minimum score is 14 and the maximum score is 70, with lower scores indicating poorer quality of life. The data presented here summarizes the change in score from baseline to endpoint (8 weeks or last observation after baseline). (NCT00481195)
Timeframe: Baseline and 8 weeks (or last observation after baseline)

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day8.2
Placebo7.4

Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) in the Quick Inventory of Depressive Symptomatology - 16 Items (QIDS-SR16)

The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Endpoint (Week 8 or last observation after baseline). (NCT00481195)
Timeframe: Baseline and 8 weeks (or last observation after baseline)

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-7.0
Placebo-6.5

Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) on 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30) - Item 4

The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Item 4 assesses hypersomnia on a scale from 0 (sleeps no longer than 7-8 hours a night) to 3 (sleeps longer than 12 hours in 24 hour period). The data presented here summarizes the change from baseline to Endpoint in the score of Item 4 assessing hypersomnia. (NCT00481195)
Timeframe: Baseline and 8 weeks (or last observation after baseline)

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-0.4
Placebo-0.2

Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) on 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30) Combination of Items 1-3

The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Items 1 - 3 assess sleep onset insomnia, mid-nocturnal insomnia, and early morning insomnia respectively each on a 0 - 3 scale. The data presented here summarizes the change from baseline to Endpoint in the combined score of these three items assessing insomnia. (NCT00481195)
Timeframe: Baseline and 8 weeks (or last observation after baseline)

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-1.6
Placebo-1.2

Change From Baseline to Week 1 in the Quick Inventory of Depressive Symptomatology - 16 Items (QIDS-SR16)

The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 1 (NCT00481195)
Timeframe: Baseline and 1 week following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-3.5
Placebo-3.7

Change From Baseline to Week 2 in the Quick Inventory of Depressive Symptomatology - 16 Items (QIDS-SR16)

The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 2 (NCT00481195)
Timeframe: Baseline and 2 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-5.0
Placebo-4.1

Change From Baseline to Week 3 in the Quick Inventory of Depressive Symptomatology - 16 Items (QIDS-SR16)

The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 3. (NCT00481195)
Timeframe: Baseline and 3 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-5.8
Placebo-5.0

Change From Baseline to Week 4 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is a 10-item scale to evaluate the overall severity of a patient's depressive symptoms, that is completed by the physician. The rating scale makes use of both observational clues as to the subject's level of depression (eg. apparent sadness) and verbal indicators of depression expressed by the patient. Each of the 10 items is graded on a 6-point scale with anchors at 2 point intervals. Total scores range from 0 to 60, with the higher number indicating more severe symptoms of depression. Here we present data summarizing the difference in MADRS score from Baseline to Week 4. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-9.6
Placebo-8.9

Change From Baseline to Week 4 in the Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)

The Q-LES-Q-SF is an instrument designed to measure general activities of daily living. It is a patient-rated quality of life questionnaire and consists of 16 items, but only the first 14 are included in the total score. Each item is rated by the patient on a scale from 1 - 5 (1=very poor, 2=poor, 3=fair, 4=good, and 5=very good). The minimum score is 14 and the maximum score is 70, with lower scores indicating poorer quality of life. The data presented here summarizes the change in score from baseline to 4 weeks. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day5.9
Placebo4.6

Change From Baseline to Week 4 in the Quick Inventory of Depressive Symptomatology - 16 Items (QIDS-SR16)

The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 4. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-6.4
Placebo-5.6

Change From Baseline to Week 4 on 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30) - Item 4

The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Item 4 assesses hypersomnia on a scale from 0 (sleeps no longer than 7-8 hours a night) to 3 (sleeps longer than 12 hours in 24 hour period). The data presented here summarizes the change from baseline to week 4 in the score of Item 4 assessing hypersomnia. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-0.2
Placebo-0.2

Change From Baseline to Week 4 on 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30) Combination of Items 1-3

The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Items 1 - 3 assess sleep onset insomnia, mid-nocturnal insomnia, and early morning insomnia respectively each on a 0 - 3 scale. The data presented here summarizes the change from baseline to week 4 in the combined score of these three items assessing insomnia. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-1.2
Placebo-1.1

Change From Baseline to Week 6 in the Quick Inventory of Depressive Symptomatology - 16 Items (QIDS-SR16)

The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 6. (NCT00481195)
Timeframe: Baseline and 6 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-7.8
Placebo-6.7

Change From Baseline to Week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is a 10-item scale to evaluate the overall severity of a patient's depressive symptoms, that is completed by the physician. The rating scale makes use of both observational clues as to the subject's level of depression (eg. apparent sadness) and verbal indicators of depression expressed by the patient. Each of the 10 items is graded on a 6-point scale with anchors at 2 point intervals. Total scores range from 0 to 60, with the higher number indicating more severe symptoms of depression. Here we present data summarizing the difference in MADRS score from Baseline to Week 8. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-13.4
Placebo-11.0

Change From Baseline to Week 8 in the Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)

The Q-LES-Q-SF is an instrument designed to measure general activities of daily living. It is a patient-rated quality of life questionnaire and consists of 16 items, but only the first 14 are included in the total score. Each item is rated by the patient on a scale from 1 - 5 (1=very poor, 2=poor, 3=fair, 4=good, and 5=very good). The minimum score is 14 and the maximum score is 70, with lower scores indicating poorer quality of life. The data presented here summarizes the change in score from baseline to 8 weeks. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day10.1
Placebo8.5

Change From Baseline to Week 8 in the Quick Inventory of Depressive Symptomatology - 16 Items (QIDS-SR16)

The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 8. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-8.2
Placebo-7.6

Change From Baseline to Week 8 on 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30) - Item 4

The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Item 4 assesses hypersomnia on a scale from 0 (sleeps no longer than 7-8 hours a night) to 3 (sleeps longer than 12 hours in 24 hour period). The data presented here summarizes the change from baseline to week 8 in the score of Item 4 assessing hypersomnia. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-0.3
Placebo-0.2

Change From Baseline to Week 8 on 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30) Combination of Items 1-3

The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Items 1 - 3 assess sleep onset insomnia, mid-nocturnal insomnia, and early morning insomnia respectively each on a 0 - 3 scale. The data presented here summarizes the change from baseline to week 8 in the combined score of these three items assessing insomnia. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-2.0
Placebo-1.6

The Mean Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)

The IDS C30 is a standardized 30 item, clinician rated scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Endpoint (either week 8 or the last observation after baseline) in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 8 weeks from start of study drug administration (or last observation after baseline)

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-15.6
Placebo-12.5

The Mean Change From Baseline to Week 1 in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)

The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 1 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 1 week following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-6.5
Placebo-4.8

The Mean Change From Baseline to Week 2 in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)

The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 2 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 2 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-10.0
Placebo-7.3

The Mean Change From Baseline to Week 3 in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)

The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 3 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 3 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-13.1
Placebo-10.7

The Mean Change From Baseline to Week 4 in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)

The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 4 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-13.7
Placebo-12.1

The Mean Change From Baseline to Week 6 in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)

The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 6 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 6 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-16.7
Placebo-13.7

The Mean Change From Baseline to Week 8 in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)

The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 8 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration

InterventionUnits on a scale (Least Squares Mean)
Armodafinil 150 mg/Day-17.8
Placebo-14.8

"Number of Patients Achieving Response at Endpoint According to the 30-item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)"

"The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data here summarizes the number of subjects in each treatment group who achieved a response (> 50% decrease from baseline in total score)." (NCT00481195)
Timeframe: Baseline, 4 and 8 weeks following start of study drug administration (or last observation after baseline)

,
InterventionParticipants (Number)
ResponseNo Response
Armodafinil 150 mg/Day4678
Placebo4776

"Number of Patients Achieving Sustained Remission at Endpoint According to the 30-item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)"

"The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data here summarizes the number of subjects in each treatment group who achieved a sustained remission (total score <= 11 that persists over the four week period from Week 4 to Week 8)." (NCT00481195)
Timeframe: Baseline, 4 and 8 weeks following start of study drug administration (or last observation after baseline)

,
InterventionParticipants (Number)
Sustained RemissionNo Sustained Remission
Armodafinil 150 mg/Day13111
Placebo8115

"Number of Patients Achieving Sustained Response at Endpoint According to the 30-item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)"

"The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data here summarizes the number of subjects in each treatment group who achieved a sustained response (> 50% decrease from baseline in total score that persisted over the four week period between Week 4 and Week 8)." (NCT00481195)
Timeframe: Baseline, 4 and 8 weeks following start of study drug administration (or last observation after baseline)

,
InterventionParticipants (Number)
Sustained ResponseNo Sustained Response
Armodafinil 150 mg/Day23101
Placebo17106

Number of Patients Achieving Remission at Endpoint According to the 30-item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)

The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data here summarizes the number of subjects in each treatment group who achieved a remission (total score <=11). (NCT00481195)
Timeframe: Baseline, 4 and 8 weeks following start of study drug administration (or last observation after baseline)

,
InterventionParticipants (Number)
RemissionNo Remission
Armodafinil 150 mg/Day3094
Placebo22101

The Number of Responders According to the Clinical Global Impression of Change - Bipolar Version (CGI BP) Measure of Depression at Endpoint (Week 8 or Last Observation After Baseline)

"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Endpoint are presented." (NCT00481195)
Timeframe: Baseline and 8 weeks (or last observation after baseline)

,
InterventionParticipants (Number)
ResponderNon Responder
Armodafinil 150 mg/Day6460
Placebo6062

The Number of Responders According to the Clinical Global Impression of Change - Bipolar Version (CGI BP) Measure of Depression at Week 1

"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 1 are presented." (NCT00481195)
Timeframe: Baseline and 1 week following the start of study drug administration

,
InterventionParticipants (Number)
ResponderNon Responder
Armodafinil 150 mg/Day12107
Placebo12105

The Number of Responders According to the Clinical Global Impression of Change - Bipolar Version (CGI BP) Measure of Depression at Week 2

"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 2 are presented." (NCT00481195)
Timeframe: Baseline and 2 weeks following the start of study drug administration

,
InterventionParticipants (Number)
ResponderNon Responder
Armodafinil 150 mg/Day2583
Placebo2684

The Number of Responders According to the Clinical Global Impression of Change - Bipolar Version (CGI BP) Measure of Depression at Week 3

"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 3 are presented." (NCT00481195)
Timeframe: Baseline and 3 weeks following the start of study drug administration

,
InterventionParticipants (Number)
ResponderNon Responder
Armodafinil 150 mg/Day3864
Placebo3268

The Number of Responders According to the Clinical Global Impression of Change - Bipolar Version (CGI BP) Measure of Depression at Week 4

"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 4 are presented." (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration

,
InterventionParticipants (Number)
ResponderNon Responder
Armodafinil 150 mg/Day4653
Placebo4255

The Number of Responders According to the Clinical Global Impression of Change - Bipolar Version (CGI BP) Measure of Depression at Week 6

"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 6 are presented." (NCT00481195)
Timeframe: Baseline and 6 weeks following the start of study drug administration

,
InterventionParticipants (Number)
ResponderNon Responder
Armodafinil 150 mg/Day4745
Placebo4349

The Number of Responders According to the Clinical Global Impression of Change - Bipolar Version (CGI BP) Measure of Depression at Week 8

"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 8 are presented." (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration

,
InterventionParticipants (Number)
ResponderNon Responder
Armodafinil 150 mg/Day5237
Placebo4741

Change From Baseline in the Dysphoric Apathy/Retardation Sub-factor (MDAR) of Montgomery-Asberg Depression Rating Scale (MADRS) at 4 Weeks.

The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment

,
Interventionscores on a scale (Mean)
Baseline Mean MDAR scoreWeek 4 Mean MDAR scoreChange from BL in mean MDAR score
Lisdexamfetamine Dimesylate (Vyvanse)13.466.36-7.08
Placebo Adjunct12.579.08-3.49

Reviews

10 reviews available for modafinil and Depression, Involutional

ArticleYear
The Potential Procognitive Effects of Modafinil in Major Depressive Disorder: A Systematic Review.
    The Journal of clinical psychiatry, 2019, 10-08, Volume: 80, Issue:6

    Topics: Adult; Central Nervous System Stimulants; Cognition Disorders; Controlled Clinical Trials as Topic;

2019
The role of eugeroics in the treatment of affective disorders.
    Psychiatria polska, 2020, Feb-29, Volume: 54, Issue:1

    Topics: Adult; Antidepressive Agents; Central Nervous System Stimulants; Depressive Disorder, Major; Evidenc

2020
The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis.
    Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:4

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder, Major; Dextroamphetami

2017
Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials.
    The Journal of clinical psychiatry, 2013, Volume: 74, Issue:11

    Topics: Antidepressive Agents; Antimanic Agents; Benzhydryl Compounds; Bipolar Disorder; Depressive Disorder

2013
Stimulants for depression: On the up and up?
    The Australian and New Zealand journal of psychiatry, 2016, Volume: 50, Issue:3

    Topics: Amphetamine; Antidepressive Agents; Benzhydryl Compounds; Bipolar Disorder; Central Nervous System S

2016
The role of dopaminergic agents in improving quality of life in major depressive disorder.
    Current psychiatry reports, 2009, Volume: 11, Issue:6

    Topics: Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Depressive Disorder, Major; Dopa

2009
[Modafinil in the treatment of depression].
    Ugeskrift for laeger, 2012, Feb-06, Volume: 174, Issue:6

    Topics: Antidepressive Agents; Benzhydryl Compounds; Bipolar Disorder; Central Nervous System Stimulants; De

2012
Executive dysfunction in major depressive disorder.
    Expert review of neurotherapeutics, 2005, Volume: 5, Issue:1

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognition Disorders; Depressive Disorder, M

2005
Pharmacological approaches to the treatment of residual symptoms.
    Journal of psychopharmacology (Oxford, England), 2006, Volume: 20, Issue:3 Suppl

    Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Benzhydryl Compounds; Benzodiazepines; Central

2006
Symptoms of fatigue and sleepiness in major depressive disorder.
    The Journal of clinical psychiatry, 2006, Volume: 67 Suppl 6

    Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Bupropion; Ce

2006

Trials

15 trials available for modafinil and Depression, Involutional

ArticleYear
A multi-pronged investigation of option generation using depression, PET and modafinil.
    Brain : a journal of neurology, 2022, 06-03, Volume: 145, Issue:5

    Topics: Adult; Cross-Over Studies; Depression; Depressive Disorder, Major; Dopamine; Humans; Modafinil; Posi

2022
Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial.
    The Journal of clinical psychiatry, 2014, Volume: 75, Issue:10

    Topics: Adult; Benzhydryl Compounds; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Drug

2014
Evaluation of Potential Pharmacokinetic Drug-Drug Interaction between Armodafinil and Aripiprazole in Healthy Adults.
    Pharmacopsychiatry, 2015, Volume: 48, Issue:4-5

    Topics: Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Benzhydryl Compounds; Cytoc

2015
Examining the efficacy of d-cycloserine to augment therapeutic learning in depression.
    Contemporary clinical trials, 2016, Volume: 48

    Topics: Antimetabolites; Benzhydryl Compounds; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycl

2016
A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression.
    The Journal of clinical psychiatry, 2010, Volume: 71, Issue:1

    Topics: Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive

2010
Modafinil reduces microsleep during partial sleep deprivation in depressed patients.
    Journal of psychiatric research, 2010, Volume: 44, Issue:13

    Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder, Major; Double-B

2010
Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study.
    The Journal of clinical psychiatry, 2010, Volume: 71, Issue:10

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antimanic Agents; Benzhydryl Compounds; Benzodiazepi

2010
Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression.
    Depression and anxiety, 2011, Volume: 28, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Central Nervous System Stimul

2011
An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy.
    Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; D

2003
Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:9

    Topics: Adult; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Di

2003
A prospective trial of modafinil as an adjunctive treatment of major depression.
    Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:1

    Topics: Adult; Aged; Antidepressive Agents; Benzhydryl Compounds; Depressive Disorder, Major; Diagnostic and

2004
Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:3

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde

2004
A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:1

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde

2005
Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study.
    CNS spectrums, 2006, Volume: 11, Issue:2

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde

2006
Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:6

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde

2007

Other Studies

21 other studies available for modafinil and Depression, Involutional

ArticleYear
High-dose armodafinil in treatment-refractory bipolar depression.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2023, Volume: 35, Issue:3

    Topics: Aged; Benzhydryl Compounds; Bipolar Disorder; COVID-19; Depressive Disorder, Major; Female; Humans;

2023
[Use of Modafinil in Co-existing Major Depression and ErectileDysfunction: A Case Report].
    Turk psikiyatri dergisi = Turkish journal of psychiatry, 2019,Summer, Volume: 30, Issue:2

    Topics: Adult; Central Nervous System Stimulants; Depressive Disorder, Major; Drug Administration Schedule;

2019
Innovation in the treatment of bipolar depression.
    The Journal of clinical psychiatry, 2014, Volume: 75, Issue:10

    Topics: Benzhydryl Compounds; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Male; Modafinil;

2014
When positive isn't positive: the hopes and disappointments of clinical trials.
    The Journal of clinical psychiatry, 2014, Volume: 75, Issue:10

    Topics: Benzhydryl Compounds; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Male; Modafinil;

2014
Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults.
    Clinical therapeutics, 2015, Feb-01, Volume: 37, Issue:2

    Topics: Adult; Anticonvulsants; Benzhydryl Compounds; Bipolar Disorder; Carbamazepine; Cytochrome P-450 CYP3

2015
A primer on confidence intervals in psychopharmacology.
    The Journal of clinical psychiatry, 2015, Volume: 76, Issue:2

    Topics: Abnormalities, Drug-Induced; Antidepressive Agents; Benzhydryl Compounds; Confidence Intervals; Curr

2015
Is there a role for psychostimulants in old age depression and apathy?
    International psychogeriatrics, 2009, Volume: 21, Issue:2

    Topics: Aged; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Dis

2009
Augmentation of dopaminergic agents for major depressive disorder.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:3

    Topics: Administration, Oral; Benzhydryl Compounds; Central Nervous System Stimulants; Combined Modality The

2009
Modafinil use in patients with a primary psychiatric illness.
    The Australian and New Zealand journal of psychiatry, 2010, Volume: 44, Issue:6

    Topics: Adult; Affect; Arousal; Benzhydryl Compounds; Bipolar Disorder; Brain Injury, Chronic; Central Nervo

2010
The use of dopaminergic and stimulant drugs for the treatment of depression.
    Journal of psychosocial nursing and mental health services, 2012, Volume: 50, Issue:2

    Topics: Amphetamines; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype

2012
Modafinil augmentation of mirtazapine in a failure-to-thrive geriatric inpatient.
    International journal of psychiatry in medicine, 2002, Volume: 32, Issue:4

    Topics: Aged; Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Cachexia; Central Nervous System Stimu

2002
Modafinil as an alternative to light therapy for winter depression.
    European psychiatry : the journal of the Association of European Psychiatrists, 2004, Volume: 19, Issue:1

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder, Major; Humans; Male; M

2004
Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report.
    Sleep medicine, 2004, Volume: 5, Issue:5

    Topics: Benzhydryl Compounds; Blood Pressure; Cataplexy; Central Nervous System Stimulants; Comorbidity; Dep

2004
A retrospective chart review of the effects of modafinil on depression as monotherapy and as adjunctive therapy.
    Depression and anxiety, 2005, Volume: 21, Issue:4

    Topics: Adult; Anxiety; Benzhydryl Compounds; Central Nervous System Stimulants; Chemotherapy, Adjuvant; Dem

2005
Modafinil-induced reversible hyperkinetic nondystonic movement disorder in a patient with major depressive disorder.
    The Journal of neuropsychiatry and clinical neurosciences, 2006,Spring, Volume: 18, Issue:2

    Topics: Aged; Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Central Nervous System Stimula

2006
Serious adverse events and the modafinil augmentation study.
    CNS spectrums, 2006, Volume: 11, Issue:5

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder, Major; Drug Synergism;

2006
Using psychostimulants for treating residual symptoms in major depression.
    Journal of psychiatry & neuroscience : JPN, 2007, Volume: 32, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Central Nervous System Stimul

2007
Ultra short manic-like episodes after antidepressant augmentation with modafinil.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Apr-01, Volume: 32, Issue:3

    Topics: Antidepressive Agents; Benzhydryl Compounds; Bipolar Disorder; Central Nervous System Stimulants; De

2008
Methylphenidate and depression.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:1

    Topics: Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Delayed-Action Prepa

2008
Visual and coenesthetic hallucinations associated with modafinil.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:2

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder, Major; Hallucinations;

2008
Modafinil monotherapy in depression.
    European psychiatry : the journal of the Association of European Psychiatrists, 2002, Volume: 17, Issue:3

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder, Major; Humans; Male; M

2002